| Molecular Formula | C15H18N2 |
| Molar Mass | 226.32 |
| Density | 1.102±0.06 g/cm3(Predicted) |
| Melting Point | 72-73 °C |
| Boling Point | 177-180 °C(Press: 4.5 Torr) |
| Solubility | DMSO: soluble5mg/mL at warmed (clear solution) |
| Appearance | powder |
| Color | white to beige |
| pKa | 7.34±0.61(Predicted) |
| Storage Condition | 2-8°C |
| In vitro study | ML204 inhibits TRPC4β-mediated elevation of intracellular calcium with an IC50 of 0.96 μm, which is 19-fold more selective for muscarinic receptor-coupled TPRC6 channels. The inhibition of TPRC4β by ML204 is independent of GPCR activation. Selective experiments showed that 10-20 μm ML204 had no significant inhibitory effect on TRPV1, TRPV3, TRPA1, TRPM8 and KCNQ2 and voltage-dependent sodium ion channels, potassium ion channels and calcium ion channels in mouse dorsal root ganglion neurons. ML204 inhibits TRPC4β activity induced by G I/o or G q/11 stimulation |
| In vivo study | ML204 (1 mg/kg; s.c.; twice a day; for 5 days) causes mortality associated with exacerbated hypothermia and decreases peritoneal leukocyte numbers and cytokines in LPS-injected mice. Animal Model: Nonfasted male C57BL/6 (2-3 months) Dosage: 1 mg/kg Administration: Subcutaneous injection, twice a day, for 5 days (prior to LPS injection) Result: Induced mortality associated with increased hypothermia in mice with LPS-induced systemic inflammatory response. |
| Hazard Symbols | Xn - Harmful![]() |
| Risk Codes | 22 - Harmful if swallowed |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 4.419 ml | 22.093 ml | 44.185 ml |
| 5 mM | 0.884 ml | 4.419 ml | 8.837 ml |
| 10 mM | 0.442 ml | 2.209 ml | 4.419 ml |
| 5 mM | 0.088 ml | 0.442 ml | 0.884 ml |